EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis

Shio Yen Tio iD, Chin Fen Neoh, David Ritchie, Lynette Chee, David C M Kong, Leon J Worth, Michelle K Yong, Monica A Slavin

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70104 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Shio Yen Tio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Invasive Fungal Infections, Antifungal Agents, Triazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hemopoietic stem cell transplant (aHSCT) recipients are at high‐risk for invasive fungal disease (IFD), even with mould‐active antifungal prophylaxis (AFP).

Methods

This was a retrospective, observational, single‐center cohort study involving 300 adult aHSCT recipients transplanted from January 2017–May 2020. Patient demographics, underlying hematological malignancy (HM), transplant characteristics and AFP were described. The primary objectives were rate and characteristics of breakthrough IFD (bIFD) within 1‐year post‐transplant.

Results

Of 300 aHSCT recipients, 195 (65%) were males; median age at transplantation was 54 years (IQR 43–62). Acute leukemia was the most common underlying HM (50%), and modified‐release posaconazole was the main primary AFP (88%). B‐IFD occurred in 26 patients (9%): 14 breakthrough invasive mould diseases (bIMD), which Aspergillus species predominated (56%), followed by Lomentospora prolificans (31%); and 12 breakthrough invasive yeast infections, with Nakaseomyces glabratus most frequently isolated. Neither Aspergillus fumigatus complex nor Candida albicans was cultured as breakthrough organisms. bIMD occurred late post aHSCT at median of 167 days, whereas breakthrough invasive yeast infection occurred at median of 21 days. Twelve patients (46%) had therapeutic‐drug‐monitoring at time of bIFD—all were within therapeutic range. All‐cause mortality at 12‐weeks from bIMD and breakthrough invasive yeast infection infections were 50% and 58%, respectively.

Conclusion

Although bIFD rate was consistent with other reports, mortality after bIFD remained significant. Use of mould‐active AFP likely explained the changing epidemiology of fungal isolates. Resistant breakthrough fungal organisms, especially L. prolificans , reflected local epidemiology. Ongoing surveillance of IFD including resistant organisms is warranted to optimize treatment and patient outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationInvasive Fungal InfectionsAntifungal AgentsTriazolesHumansMaleFemaleMiddle AgedRetrospective StudiesAdultTransplantation, HomologousHematologic NeoplasmsTransplant Recipients

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantbreakthrough invasive fungal diseaseinvasive mould diseaseinvasive yeast infectionsposaconazole prophylaxis

Substanzen

posaconazoleAntifungal AgentsTriazoles

Autor:innen und Institutionen

  • Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • National Centre For Infections in Cancer, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Victorian Infectious Diseases Service (VIDS), Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Clinical Haematology, Peter Maccallum Cancer Centre, The Royal Melbourne Hospital, Melbourne, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Shio Yen Tio

Förderung

  • MSD Australia

Zitieren

APA

Tio, S. Y., Neoh, C. F., Ritchie, D., Chee, L., Kong, D. C. M., Worth, L. J., Yong, M. K., & Slavin, M. A. (2025). The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis. Transplant Infectious Disease. https://doi.org/10.1111/tid.70104

Vancouver

Tio SY, Neoh CF, Ritchie D, Chee L, Kong DCM, Worth LJ, et al. The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis. Transplant Infectious Disease. 2025. doi:10.1111/tid.70104

BibTeX
@article{Tio2025,
  author = {Tio, Shio Yen and Neoh, Chin Fen and Ritchie, David and Chee, Lynette and Kong, David C M and Worth, Leon J and Yong, Michelle K and Slavin, Monica A},
  title = {The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70104}
}
Kostenlos starten →